Clinical Labeling

 

Clinical Labeling - Overview

During drug development, companies may utilize a variety of clinical labeling-related tools that employ target labeling to facilitate drug development, while aligning with the desired marketing and labeling objectives in the development program design/study design, and drafting the Clinical Overview (CO).

It is important for companies to employ a modular approach while collecting safety and efficacy information across various types of clinical labels. This would effectively help investigators and sponsors by presenting and updating a focused and dedicated Development Core Safety Information (DCSI) section that can conveniently be placed under the different clinical categories. Furthermore, the DCSI develops into the Company Core Safety Information (CCSI) that is included in the first Company Core Data Sheet (CCDS) and is utilized for the product's market entry. Drafting a thorough CO comprising the scope and critical issues in the drug’s clinical developmental program is also required to support the documentation for the assessors.

Clinical Labeling - Expertise

  • Creation and review of Investigational Brochure (IB)
  • Development of Target Labeling (TL)/Target Profile (TP)
  • Development and review of Developmental Core Data Sheets (DCDS) & DCS
  • Development and review of FDA Target Product Profile (TPP), EU-draft SmPC (dSmPC)
Clinical Labeling

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​